BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-06-15 06:10 |
BerGenBio ASA - Mandatory notification of trade, allocations to primary insider…
|
English | 232.9 KB | ||
| 2023-06-15 06:10 |
BerGenBio ASA - Mandatory notification of trade, allocations to primary insider…
|
English | 4.8 KB | ||
| 2023-06-14 15:21 |
BergenBio ASA - Disclosure of large shareholding
|
English | 1.1 KB | ||
| 2023-06-14 14:48 |
BerGenBio - Disclosure of large shareholding
|
English | 728 bytes | ||
| 2023-06-14 13:20 |
BerGenBio ASA - Correction of final results of the Rights Issue
|
English | 9.1 KB | ||
| 2023-06-14 11:30 |
BerGenBio ASA - Final results of the Rights Issue
|
English | 11.4 KB | ||
| 2023-06-13 18:30 |
BerGenBio ASA - Preliminary results indicates an oversubscribed Rights Issue of…
|
English | 9.9 KB | ||
| 2023-06-13 07:49 |
Mandatory notification of trade by Primary Insiders and close associates
|
English | 67.2 KB | ||
| 2023-06-13 07:49 |
Mandatory notification of trade by Primary Insiders and close associates
|
English | 1.7 KB | ||
| 2023-06-13 05:00 |
BerGenBio ASA - Last day of the Subscription Period in the Rights Issue
|
English | 10.1 KB | ||
| 2023-06-08 20:01 |
Mandatory notification of trade by Primary Insiders and close associates
|
English | 52.8 KB | ||
| 2023-06-08 20:01 |
Mandatory notification of trade by Primary Insiders and close associates
|
English | 1.3 KB | ||
| 2023-06-07 15:20 |
Mandatory notification of trade by Primary Insiders and close associates
|
English | 155.5 KB | ||
| 2023-06-07 15:20 |
Mandatory notification of trade by Primary Insiders and close associates
|
English | 3.4 KB | ||
| 2023-06-07 05:00 |
BerGenBio ASA - Last day of trading in Subscription Rights
|
English | 9.7 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
